Introduction {#s1}
============

Removal of introns from pre-messenger RNA (pre-mRNA) is an essential step in eukaryotic gene expression. This process is catalysed by a large and dynamic RNA-protein assembly called the spliceosome, which consists of five small nuclear ribonucleoprotein particles (U1, U2, U4, U5 and U6 snRNPs) and numerous non-snRNP proteins ([@bib66]). U1 snRNP recognizes a short sequence at the 5′-splice site (5′SS) of pre-mRNA through basepairing between the 5′-end of U1 snRNA and the 5′SS sequence ([@bib24]; [@bib68]; [@bib57]; [@bib54]) and promotes an ordered assembly of the four remaining snRNPs to form the spliceosome, which then undergoes extensive conformational and compositional remodelings to become catalytically active ([@bib66]). During activation, the interaction between U1 snRNP and the 5′SS is disrupted by RNA helicase Prp28 ([@bib60]) and then the 5′SS intron sequence base-pairs with part of the ACAGAGA box in U6 snRNA ([@bib51]; [@bib52]; [@bib63]; [@bib20]; [@bib25a]; [@bib58]); whilst the 5′ exon interacts with U5 snRNA loop I for the first *trans*-esterification reaction ([@bib37]). U1 snRNP is also an important regulator of mRNA 3′ end cleavage and polyadenylation ([@bib1]; reviewed in [@bib59]).

Human U1 snRNP comprises U1 snRNA, seven Sm proteins (SmB/SmB′, SmD1, SmD2, SmD3, SmE, SmF and SmG) and three U1-specific proteins (U1-70K, U1-A and U1-C) ([@bib16]; [@bib2]). We reported the structure of the functional core of U1 snRNP ([@bib41]) based on an experimental electron density map at 5.5 Å resolution to which we fitted previously-determined structures of protein components ([@bib19]; [@bib34]; [@bib26]). The most striking feature of the structure is the N-terminal region of U1-70k, which extends from its RRM through a long α-helix and wraps around the Sm protein assembly so that its N-terminus makes contact with U1-C protein, thus accounting for the requirement of U1-70k for U1-C binding ([@bib35]; [@bib15]). In this crystal the 5′-end of U1 snRNA pairs with its symmetry-related counterpart, mimicking the binding of the 5′SS of pre-mRNA to U1 snRNP. The Zn-finger domain of U1-C is located adjacent to this RNA duplex but the low-resolution map was insufficient for analysis of the RNA-protein contacts in atomic detail and hence it was not clear how U1-C contributes to the recognition of the 5′SS. The structure of U1 snRNP from HeLa cells, treated with chymotrypsin, was subsequently reported ([@bib64]). Although this crystal had a DNA oligonucleotide with the 5′SS consensus sequence bound to the 5′-end of U1 snRNA, the N-terminal end of U1-70k together with U1-C protein were lost by protease treatment. Hence neither of these structures revealed molecular details of 5′SS recognition by U1 snRNP.

In order to gain crucial insight into the mechanism of 5′SS recognition we continued our attempts to grow crystals of U1 snRNP diffracting to high resolution but this proved unsuccessful because the inherent mobility of long RNA helices arranged as a 4-way junction prevented the formation of well-diffracting crystals ([@bib40]; [@bib64]). Hence we designed two sub-structures of U1 snRNP, with exclusively human sequences, based on our 5.5 Å resolution structure and determined their crystal structures at high resolution.

Yeast U1 snRNP, when compared to the human particle, contains a larger and more complex snRNA, which is associated with many protein factors (Prp39, Snu71, Prp40, Prp42, Nam8, Snu56, Urn1 and Prp5), which have no counterparts in human U1 snRNP ([@bib36]). However, despite these differences, the sequence of the 5′-single stranded region of U1 snRNA (nts 1--10) is invariant from yeast to human (<http://rfam.sanger.ac.uk/>) and the amino acid sequence of the Zn-finger of U1-C (yeast Yhc1) is also highly conserved ([@bib34]). Hence the 5′SS of pre-mRNA is expected to make exactly the same contacts with the 5′ end of U1 snRNA and U1-C in human and yeast U1 snRNPs. However, some positions of the 5′SS have quite different nucleotide bias in yeast and human genes ([@bib3]). In human the 5′SS sequences processed by major spliceosomes are degenerate but show significant overall complementarity to the sequence of the 5′ end of U1 snRNA ([@bib24]). In contrast the 5′SS intron sequence of yeast pre-mRNA is stringently conserved to be GUAUGU ([@bib3]). Upon activation of the yeast spliceosome, the intron sequence, UGU (+4, +5 and +6), pairs with ACA within the ACAGAGA sequence in U6 snRNA and hence these nucleotides are selected to be nearly invariant ([@bib51]; [@bib20]). Cross-linking studies revealed interaction of the same regions of U6 snRNA and the 5′SS sequence in human but the sequence requirement is less obvious ([@bib52]; [@bib63]). Prp8 is also known to influence the selection of the 5′SS nucleotide (reviewed in [@bib13]; [@bib11]). Furthermore in humans constitutive or alternative splicing factors facilitate the binding of U1 snRNP to weak splice sites. As discussed above, the 5′SS is subjected to multiple selections which differ in yeast and human and give rise to different nucleotide biases at 5′SS. The strength of variant 5′SS sequences is assessed by relative usage of competing 5′SS ([@bib49], [@bib47]) which is determined not only by the affinity of 5′SS to U1 snRNP but also by multiple factors ([@bib48]).

Our two new crystals together reveal the structures of the substantial parts of U1 snRNP at high resolution and provide crucial insights into the mechanism of pre-mRNA recognition by U1 snRNP. In particular, we find that U1-C makes no base-specific contacts with the 5′SS sequence. Also, by measuring the intrinsic affinity of recombinant U1 snRNP for various 5′SS sequences we disentangle the role played by the U1 snRNP from the other complexities of 5′SS recognition, and assess the relative contributions of U1 snRNA and U1-C protein in light of our crystal structure.

Results and discussion {#s2}
======================

A minimal U1 snRNP consisting of seven Sm proteins, the N-terminal peptide of U1-70k, U1-C and a truncated U1 snRNA was designed based on the 5.5 Å resolution structure ([Figure 1A](#fig1){ref-type="fig"}; [Figure 1---figure supplements 1 and 2](#fig1s1 fig1s2){ref-type="fig"}) ([@bib41]). A large portion of RNA attached to Helix H through the 4-way junction was replaced by a kissing-loop ([@bib10]) to facilitate crystal contacts ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). However, this eliminated the binding site (stem-loop I) for the U1-70k RRM (RNA-recognition motif) ([@bib43]) and thus weakened the binding of the U1-70k N-terminal peptide to the snRNP core domain ([@bib35]; [@bib15]). In order to stabilize its binding we fused the N-terminal 59 residue peptide of U1-70k to SmD1 via a Gly--Ser linker (70kSmD1F, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The reconstituted complex was stable and yielded crystals diffracting to 3.3 Å ([Table 1](#tbl1){ref-type="table"}). The second crystal (U1A70kF-RNA) contains residues 60--216 of U1-70k and the entire U1 snRNA stem-loop I. In order to promote interaction of the long α-helix of U1-70k with the RNA stem we fused it to the U1-A RRM and capped the RNA with the apical loop of stem-loop II such that the α-helix is anchored to the RNA stem ([Figure 1---figure supplements 1 and 2](#fig1s1 fig1s2){ref-type="fig"}). The crystal structure of this complex was determined at 2.5 Å ([Figure 1B](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Phases for both crystal structures were determined by molecular replacement.10.7554/eLife.04986.003Figure 1.Crystal structures of the two sub-structures of U1 snRNP.(**A**) Crystal structure of the minimal U1 snRNP with the 5′-splice site RNA determined at 3.3 Å resolution. Label H indicates U1 snRNA helix H; H0 indicates the first alpha helix of SmD2 protein. (**B**) Crystal structure (U1A70kF-RNA) of the remainder of U1-70k (residue 60--216) bound to stem-loop I of U1 snRNA determined at 2.5 Å resolution. RRM1 of U1A is fused to the residues 60--216 of U1-70k via Gly--Ser linker. Stem-loops I and II of U1 snRNA form a dumb-bell structure. (**C**) Crystal structures of the two sub-structures placed into the experimental electron density map at 5.5 Å of U1 snRNP ([@bib41]).**DOI:** [http://dx.doi.org/10.7554/eLife.04986.003](10.7554/eLife.04986.003)10.7554/eLife.04986.004Figure 1---figure supplement 1.Protein constructs used in this study.(**A**) The schematic diagram of the domain architecture of U1 snRNP proteins is shown with horizontal bars. The thinner lines below the bars represent the constructs used for crystallization: blue lines for sequences used in the U1A70kF fusion protein, red lines for sequences used in the 70kSmD1F fusion protein, and black lines indicate the extent of protein constructs used in minimal U1 crystallisation. For binding assays, U1 snRNP was reconstituted with full-length proteins except U1-70k (2--216) and SmB (1--174). (**B**) The fusion protein constructs were designed using a (Gly--Ser) linker (GS, pink). U1A70kF is used for the determination of U1-70k (60--216) fragment with Stem-loop I RNA. 70kSmD1F is used for the minimal U1 snRNP domain crystallization.**DOI:** [http://dx.doi.org/10.7554/eLife.04986.004](10.7554/eLife.04986.004)10.7554/eLife.04986.005Figure 1---figure supplement 2.The U1 snRNA constructs used for this work.(**A**) Full-length U1 snRNA is used for in vitro reconstitution and further biochemical experiments. Sequences within dashed rectangles indicate the 5′-end variations of U1 snRNA used in biochemical experiments. U1 + Ψ construct contains both 2′-O-methyl groups on A1 and U2 as well as pseudo-uridines at position 5 and 6. U1 − Ψ construct has 2′-O-methyl modifications, but has normal uridines instead of pseudo-uridines. (**B**) The minimal U1 snRNA (SmKCm) construct replaces the 4-way junction with a kissing loop. (**C**) In SL1·SL2 RNA, the apical region of stem-loop 2 (U1 snRNA nucleotides 61--78) is shown in red, stem-loop 1 (U1 snRNA nucleotides 17--47) in black and other nucleotides are shown in cyan. Bases in stem-loop 1 and 2 are numbered as in natural human U1 snRNA.**DOI:** [http://dx.doi.org/10.7554/eLife.04986.005](10.7554/eLife.04986.005)10.7554/eLife.04986.006Table 1.Crystallographic data collection and refinement statistics**DOI:** [http://dx.doi.org/10.7554/eLife.04986.006](10.7554/eLife.04986.006)Minimal U1U1A70kF·RNAData collection Space groupP2~1~2~1~2~1~C2 Cell dimensions a, b, c (Å)120.4, 172.6, 256.380.2, 66.6, 93.7 α, β, γ (°)90.0, 90.0, 90.090.0, 111.0, 90.0 Wavelength (Å)0.97951.0332 Resolution (outer shell) (Å)69.67 − 3.30 (3.36 − 3.30)44.00 − 2.50 (2.64 − 2.50) Unique observations80,571 (4538)15,967 (2301) Redundancy4.6 (4.7)3.7 (3.7) Completeness99.5 (99.3)99.1 (99.4) R~merge~[\*](#tblfn1){ref-type="table-fn"}0.153 (0.846)0.076 (0.350) R~p.i.m.~[†](#tblfn2){ref-type="table-fn"}0.100 (0.534)0.047 (0.210) Mn(\[I\]/sd\[I\])172.1 (2.7)11.0 (3.2)Refinement Resolution (Å)3.302.50 Number of reflections74,96015,164 R~work~/R~free~0.209/0.2550.203/0.258 Number of atoms26,9453248 Mean B-factor99.249.5 R.m.s.d. bond length (Å)0.0100.012 R.m.s.d. bond angles (°)1.531.67 Ramachandran statistics for protein residues [‡](#tblfn3){ref-type="table-fn"} In preferred regions2534 (96.31%)228 (96.61%) In allowed regions96 (3.65%)8 (3.39%) Outliers1 (0.04%)0[^3][^4][^5]

The structure of the minimal U1 snRNP fits well into the 5.5 Å electron density except for a slight tilt of the duplex between pre-mRNA and the 5′-end of U1 snRNA ([Figure 1C](#fig1){ref-type="fig"}) ([@bib41]). In the previous structure the fortuitous interaction between the 5′-end of U1 snRNA from two symmetry-related complexes could have distorted the orientation of this RNA duplex. Hence we believe that the minimal U1 snRNP, with the consensus 5′SS oligonucleotide bound to the 5′-end of U1 snRNA, represents the 5′SS-U1 snRNP interaction in the whole U1 snRNP. The overall structure of the core domain is very similar to that of the U4 snRNP core domain, which consists of seven Sm proteins and U4 snRNA ([@bib27]) and the Sm folds of the seven Sm protein assemblies of the two structures (PDB code: 4PJO and 4WZJ) superimpose with rmsd of 0.55 Å. However, there are some noteworthy differences ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In the minimal U1 snRNP, helix H0 of SmD2 points into the minor groove of helix H ([Figure 1A](#fig1){ref-type="fig"}), buttressing it, a feature already evident at 5.5 Å ([@bib41]). The nonamer Sm site sequence (AAUUUGUGG in U1 snRNA and AAUUUUUGA in U4 snRNA) has been reported as a minimal RNA oligonucleotide to promote Sm core domain assembly ([@bib44]). In U1 snRNP each base of the first seven nucleotides of the nonamer, AAUUUGU (A125 to U131), interacts one-to-one with SmF-SmE-SmG-SmD3-SmB-SmD1-SmD2 in the pockets formed by four key residues at equivalent positions in the L3 and L5 loops of the Sm fold except for the interaction of G130 with SmD1 ([Figure 2](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In the protease-treated U1 snRNP structure ([@bib64]), G132 was placed in the nucleotide-binding pocket in SmF but our structure unambiguously shows that A125 occupies this pocket. The U4 core snRNP structure has now been refined to an R~free~ of 22.4% (Li, Leung, YK, CO and KN, manuscript in preparation; PDB code: 4WZJ) and the new model shows that whereas previously the G equivalent to G132 was also incorrectly placed in SmF ([@bib27]) the Sm site nucleotides bind in a similar manner in both minimal U1 and U4 core domain, except for SmD1. The fourth U of the U4 Sm site sequence is replaced by G in U1 snRNA in the majority of species including humans (<http://rfam.sanger.ac.uk/>) ([@bib4]). A large guanine base cannot be accommodated in SmD1 and hence it lies above His37 of SmB outside the central hole ([Figure 2](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}). In the Sm site sequence the phosphate groups of A126, U130 and U131 come close and are stabilized by a hydrated Mg^++^ ion ([Figure 2](#fig2){ref-type="fig"}). The last two nucleotides of the nonamer, G132 and G133, fit into the binding pocket formed by SmD1-SmD2 and SmF-SmE, respectively ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).10.7554/eLife.04986.007Figure 2.Stereoview showing binding of U1 snRNA at the central hole of the Sm protein assembly.The refined model is overlaid onto the 3.3 Å electron density map (2Fo − Fc) contoured at 1.5σ. Electron density for A125 and the phenol ring of SmF Y39, which stacks on it, is weak. Hydrated magnesium ion is found in the central hole (grey, Mg^++^; red, water). SmD3, purple; SmB, dark blue; SmD1, blue; SmD2, cyan; SmF, brown; SmE, yellow; SmG, green.**DOI:** [http://dx.doi.org/10.7554/eLife.04986.007](10.7554/eLife.04986.007)10.7554/eLife.04986.008Figure 2---figure supplement 1.Interaction between the Sm site nucleotides and Sm proteins in the central hole of the Sm protein assembly.(**A**), A125. The U2 snRNA Sm site has a guanine at this position. SmD2 His62 and SmF Tyr39 and Asn41 are all loop 3 (L3) residues of their respective proteins; (**B**), A126 is contacted by SmE L3 residues Tyr53 and Asn55; (**C**), U127 binding pocket comprises SmG L3 residues Phe34 and Asn39, and loop 5 (L5) residue Arg63; (**D**), U128 stacks between SmD3 L3 residue Asn38 and L5 residue Arg64, and also contacts L3 residue Asn40; (**E**), U129 binds in a pocket formed from SmB L3 residues His37 and Asn39, and L5 residue Arg73; (**F**), G130 is too large to fit in a binding pocket the same way as the other U1 Sm site nucleotides and lies above U124. Its purine base contacts SmB L3 residue Lys36. The nucleotide corresponding to G130 is a U in the U4 snRNA Sm site, which is accommodated into the nucleotide binding pocket in SmD1 ([@bib27]); (**G**), U131 base is accommodated in a pocket consisting of SmD2 L3 residues His62 and Asn64, and L5 residue Arg102; (**H**), G132 makes several interactions with the ribose phosphate backbone of neighbouring nucleotides. It does not interact with 'key residues' but stacks between the side-chains of SmD2 loop 2 (L2) residue Arg47 and SmD1 L2 residue Lys20, and contacts SmD1 β5 residue Arg66. The nucleotides equivalent to A126 and G132 were misplaced in the original U4 core snRNP structure ([@bib27]) but show interactions similar to those observed here after further refinement (Li J, Leung AKW, CJO, YK and KN, manuscript in preparation).**DOI:** [http://dx.doi.org/10.7554/eLife.04986.008](10.7554/eLife.04986.008)10.7554/eLife.04986.009Figure 2---figure supplement 2.The nucleotides G132, G133 and U134 in the central hole of the Sm protein assembly.**DOI:** [http://dx.doi.org/10.7554/eLife.04986.009](10.7554/eLife.04986.009)

In the original 5.5 Å resolution map we roughly modelled the first 60 residues of U1-70k using seleno-methionine derivatives of mutants of U1-70K (L9M, I19M, E31M, I41M, E49M, E61M and I75M). In the 3.3 Å structure almost the entire length of the U1-70k N-terminal peptide is well ordered and its interaction with the core domain is revealed in detail ([Figure 3](#fig3){ref-type="fig"}). Residues 49--58, containing a type II proline helix (Pro55, Pro56 and Pro57), interact exclusively with SmD2 and its binding to SmD2 is stabilized by salt-bridges and hydrogen bonds ([Figure 3A](#fig3){ref-type="fig"}). The U1-70k residues 39--49 are wedged in the crevice between SmD2 and SmF ([Figure 3B](#fig3){ref-type="fig"}). Then the U1-70k peptide crosses the central hole where it interacts with the backbone and bases of stem IV (A135 to G138) of U1 snRNA ([Figure 3C](#fig3){ref-type="fig"}). The 3′ stem of U4 snRNA (stem II) blocks the path of the U1-70k peptide in the U4 core domain and hence the binding of this peptide is snRNA dependent ([@bib27]). The U1-70k residues 10--31 make extensive contacts as an extended peptide with SmD3 and the β4 strand of SmB ([Figure 3D](#fig3){ref-type="fig"}; [Figure 4A](#fig4){ref-type="fig"}). The residues 6--12 of U1-70k form a 3~10~ helix and together with its N-terminal region contact the long helix B of U1-C to stabilize U1-C binding ([Figure 4A](#fig4){ref-type="fig"}). Apart from the interaction with U1-70k, U1-C interacts exclusively with SmD3. Helix A and β1 of the Zn-finger and part of long Helix B of U1-C sit on the concave surface of SmD3 made by the N-terminal helix 1, β2 strand and loop 2 and a short α-helix made by the C-terminal tail. The interface between U1-C and SmD3 is not tightly packed and is stabilized by salt-bridges and hydrogen bonds ([Figure 4A](#fig4){ref-type="fig"}). The R21Q mutation in U1-C weakens its binding to U1 snRNP by about 10-fold ([@bib34]).10.7554/eLife.04986.010Figure 3.The path of the N-terminal peptide of U1-70k.The N-terminal 60 residues of U1-70k run along the interface between SmD2 and SmF, cross the central hole and are wedged between SmB and SmD3 (Inset shows the overview). (**A**) Residues 50--58 interact with loop 1 and β1 of SmD2. Three consecutive Proline residues (Pro54--Pro56) form type II proline helix. (**B**) Residues 39--49 of U1-70k are wedged between SmF and SmD2. (**C**) The U1-70k peptide crosses the central hole where it interacts with nucleotides preceding stem-loop IV. In U4 snRNP the 3′ helix is partially buried in the central hole and hence U4 snRNA and U1-70k peptide are mutually exclusive ([@bib27]). (**D**) Residues 16--23 of U1-70k are wedged between SmD3 and SmB.**DOI:** [http://dx.doi.org/10.7554/eLife.04986.010](10.7554/eLife.04986.010)10.7554/eLife.04986.011Figure 4.U1-C contacts the duplex between the 5′-end of U1 snRNA and the 5′-splice site.(**A**) U1-C sits on SmD3 and its binding is stabilised by the N-terminus of U1-70k. (**B**) U1-C forms hydrogen bonds with the sugar-phosphate backbone atoms but makes no contact with RNA bases. On the 5′SS strand, nucleotides are colored teal for exonic and fawn for intronic sequence. (**C**) Schematic representation of the 5′-splice site recognition. Red dotted lines, hydrogen bonds made by amino acid side chains of U1-C; blue dotted lines, hydrogen bonds made by main chain atoms of U1-C. The 5′SS nucleotides are color-coded as in panel **B**.**DOI:** [http://dx.doi.org/10.7554/eLife.04986.011](10.7554/eLife.04986.011)

Natural U1 snRNA has a tri-methyl-guanosine cap attached to the 5′-end but our U1 snRNA has a 5′-triphosphate resulting from in vitro transcription instead ([Figure 1---figure supplement 2A,B](#fig1s2){ref-type="fig"}). It also has uridines at positions 5 and 6 instead of the pseudo-uridines found in natural U1 snRNA ([@bib45]). Pseudo-uridines at these positions are conserved from yeast to human U1 snRNA ([@bib31]). Only poorly diffracting crystals were obtained with pseudo-uridines at these positions. In the minimal U1 snRNP crystal, nucleotides 3 to 10 of U1 snRNA form Watson-Crick basepairs with the AG/GUAAGU sequence of the pre-mRNA strand ([Figure 4B--C](#fig4){ref-type="fig"}) where / marks the splice junction. The minor groove of the RNA duplex between the 5′SS and the 5′-end of U1 snRNA interacts with U1-C on the surface made by Helix A and the β1 strand. Several amino-acid side chains and main chain atoms of U1-C form hydrogen bonds with the 2′OH groups and phosphate oxygen atoms of both strands of RNA near the splice junction ([Figure 4B--C](#fig4){ref-type="fig"}). However, U1-C makes no contacts with the RNA bases ([Figure 4B](#fig4){ref-type="fig"}). At an early stage of spliceosomal assembly, U1 snRNP binds to the 5′SS and U2 auxiliary factor (U2AF) and splicing factor 1 (SF1) bind to the 3′ splice site and branch point resulting in the formation of E complex. A double mutant (R28G, K29S) of U1-C fails to enhance the formation of E complex ([@bib67]). The side-chains of Arg28 and Lys29 are located close to the phosphate backbone of U1 snRNA or 5′SS RNA but their side chains have no density in our map. The 5′-triphosphate of U1 snRNA is close to Glu32 and Asp36 of U1-C and their electrostatic repulsion may prevent stable interaction of the tri-methylguanosine cap with U1-C, thus allowing the pre-mRNA strand to gain access to bases of the 5′-end of U1 snRNA to pair.

Interaction between U1-70k and stem-loop I {#s2-1}
------------------------------------------

The first 215 residues of U1-70k are conserved well from yeast to human (48% sequence similarity), suggesting that this region has an evolutionarily conserved essential function, whereas the C-terminal region, predicted to be poorly structured, has diverged considerably. Some alternative splicing factors are known to bind to this region ([@bib22]; [@bib17]; [@bib7]). The U1A70kF-RNA crystal structure ([Figure 1B](#fig1){ref-type="fig"}) reveals the interaction between stem-loop I and U1-70k in detail, illustrating a new mode of RRM-RNA interaction. The canonical RRM domain is known to bind with RNA through RNP1 and RNP2 motifs as first observed in the U1A- stem loop II complex structure ([@bib39]). The RRMs of U1-A and U1-70k have very similar structures (the β-strands and α-helices of the two RRMs superimpose with an rmsd of 0.70 Å) ([Figure 5A--B](#fig5){ref-type="fig"}) whereas the RNA loops bound to these RRMs have strikingly different structures ([Figure 5C--D](#fig5){ref-type="fig"}). The U1-A bound RNA loop has an open structure with ten nucleotide bases splayed out ([Figure 5B,D](#fig5){ref-type="fig"}) ([@bib39]). Bases of the first seven loop nucleotides show stacking interactions, either with adjacent bases or with protein side chains, while the last three nucleotides are poorly ordered. In contrast, the U1-70k bound RNA loop 1 with 11 loop nucleotides ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) is stabilized by base stacking interactions and basepairing of nucleotides within the loop and hence it is effectively a five-nucleotide loop ([Figure 5A--C](#fig5){ref-type="fig"}). In U1-A the polypeptide loop between β2 and β3 (loop 3) protrudes through the RNA loop, stabilising it in an open conformation ([Figure 5B](#fig5){ref-type="fig"}) whereas loop 3 of U1-70k forms a β-turn and embraces C33 and G34 ([Figure 5A](#fig5){ref-type="fig"}). The bases of C33 and G34 stack with each other and are sandwiched between the side chains of Arg191 and Lys138, which form salt-bridges with the phosphate groups of C33 and G34 ([Figure 6A](#fig6){ref-type="fig"}). The second residue of RNP2 motif (Phe106) and the fifth residue of RNP1 motif (Phe148) show stacking interactions with the bases of C31 and A32 ([Figure 6B](#fig6){ref-type="fig"}) as commonly observed in the RRM-RNA complexes ([@bib39]). The RNA loop is closed by a trans WC/Hoogsteen base pair formed between A29 and A36 ([Figure 6C](#fig6){ref-type="fig"}). The base of G28, instead of forming a base pair with G37, flips out from the RNA helix and is sandwiched between the side chains of Arg172 and Tyr112, while the guanidinium group of Arg200 fills the gap ([Figure 6D](#fig6){ref-type="fig"}). The stacking interaction between G28 and Tyr112 accounts for the UV-crosslinking of these residues in U1 snRNP ([@bib62]). On the opposite strand the bases A35, A36, G37 and G38 continuously stack ([Figure 6C--D](#fig6){ref-type="fig"}). U30 is packed against the side chain of Leu175 and forms a hydrogen bond with the side chain of Asp177 and the exocyclic amino group of the adjacent C31 ([Figure 6E](#fig6){ref-type="fig"}). The stacking interaction between U30 and Leu175 is consistent with the UV-crosslinking of these residues ([@bib62]).10.7554/eLife.04986.012Figure 5.RRMs of U1-A and U1-70k show distinct recognition modes of stem-loop I and II.(**A**) Interaction of stem-loop I with U1-70k RRM. (**B**) Interaction of stem-loop II with U1-A RRM. (**C**) Schematic representation of RNA-protein contacts between U1-70k RRM and stem-loop I of U1 snRNA. (**D**) Schematic representation of detailed RNA-protein contacts between U1-A RRM and stem-loop II. (**E**) Regions of U1-70k flanking the RRM folds onto RNA loop and make extensive contacts with RNA. (**F**) Apical loop I is completely covered by U1-70k.**DOI:** [http://dx.doi.org/10.7554/eLife.04986.012](10.7554/eLife.04986.012)10.7554/eLife.04986.013Figure 6.Detailed RNA-protein contacts between U1-70k RRM and stem-loop I of U1 snRNA.(**A**) C33 and G34 embraced by U1-70k loop 3. (**B**) C31 and A32 stack onto Phe106 and Phe148 residues of the beta sheet. (**C**) The last three loop nucleotides stack continuously on G38 of the loop-closing base pair. (**D**) The base of G28 is flipped out from the RNA helix and its place is taken by Arg200, which, along with A29 and Arg190, continues the helical stacking of the stem. (**E**) U30 is packed against the hydrophobic side chains of Leu175 and Leu196. In all cases nitrogen atoms are shown in blue, oxygen in red and phosphorus in magenta. Hydrogen bonds are represented as dashed lines. Carbon atoms are coloured grey in RNA, orange in U1-70k.**DOI:** [http://dx.doi.org/10.7554/eLife.04986.013](10.7554/eLife.04986.013)

The most unusual feature of the U1-70k complex is that the regions flanking the RRM fold, which have no apparent secondary structural elements, make extensive interactions with the RNA loop bound on the surface of the β-sheet of the RRM, almost completely burying the RNA loop ([Figure 5E--F](#fig5){ref-type="fig"}). The C-terminal region following the RRM folds onto the RNA and runs along the shallow minor groove by forming an extensive network of hydrogen bonds. Similarly, the region between helix 0 and the RRM folds onto the RNA.

Mechanism of 5′SS recognition {#s2-2}
-----------------------------

The crystal structure of the minimal U1 snRNP has revealed in detail molecular contacts between U1 snRNP and a 5′SS RNA with the consensus sequence. The role of U1-C in stabilising the 5′SS binding was first shown by [@bib14] using 172 nucleotide pre-mRNA. We measured binding of U1 snRNP to a \[^32^P\]-labelled 5′SS oligonucleotide by filter-binding assay ([Figure 7A](#fig7){ref-type="fig"}). The affinity of U1 snRNP without U1-C (U1 snRNP\[ΔU1-C\]) for the wild type 5′SS oligonucleotide increases by between three and fourfold on addition of U1-C ([Figure 7A](#fig7){ref-type="fig"}). In order to assess the contribution of the molecular contacts revealed by the crystal structure in 5′SS sequence selection we next assayed binding of variant 5′SS oligonucleotides to U1 snRNP containing uncapped, but otherwise fully authentic, U1 snRNA.10.7554/eLife.04986.014Figure 7.Influence of nucleotide substitutions at the 5′-splice site on U1 snRNP binding.(**A**) Filter-binding results for U1 snRNP reconstituted with and without U1-C to \[^32^P\]-labelled 5′ splice site oligonucleotide. By curve fitting, the Kd with U1-C is 4.7 ± 0.8 nM and without U1-C is 15.8 ± 2.5 nM. CPM, counts per minute. (**B**) Nucleotides found at each position of the 5′-splice site of the U2-type introns. Adapted from [@bib46]. A, green; C, blue; G, black; U, red. Numbers for highly conserved positions are highlighted in red. (**C**) Competition assays of mutant 5′SS RNA binding to U1 snRNP containing U1C and uncapped but fully modified U1 snRNA. The 5′SS oligonucleotide with +1C, +5C, −1C and +2C substitutions compete weakly with the wild type oligonucleotide. In panels **C**--**F**, mP is an arbitrary unit of fluorescence polarization and error bars indicate standard error. (**D**) Competition assay with 5′SS oligonucleotides with +3G, +4G, +3U, +4U substitution and the wild type. 5′SS oligonucleotide with +2C substitution is included for comparison. (**E**) Same as in **B** except that U1 snRNP lacks U1-C. (**F**) Same as in **C** except that U1 snRNP lacks U1-C.**DOI:** [http://dx.doi.org/10.7554/eLife.04986.014](10.7554/eLife.04986.014)

Within the 5′SS of human genes processed by the major spliceosome, the most frequently observed nucleotides at each position of pre-mRNA from −3 to +6 form a Watson-Crick basepair with a nucleotide of the 5′-end of U1 snRNA ([Figure 4](#fig4){ref-type="fig"}; [Figure 7B](#fig7){ref-type="fig"}). The observed frequency tends to be higher in the middle and taper off towards both ends because mismatches affect the stability of the duplex less when they are further away from the middle. The first two intron nucleotides, which pair with C8 and A7 of U1 snRNA, are nearly invariantly GU ([@bib3]; [@bib56]) ([Figure 4C](#fig4){ref-type="fig"}; [Figure 7C](#fig7){ref-type="fig"}). The nucleotides at +3 and +4 pair with Ψ6 and Ψ5 of U1 snRNA, respectively, and A/G are found at +3 but A is found predominantly at +4. G is preferred at positions −1 and +5 ([Figure 7B](#fig7){ref-type="fig"}), which pair with C9 and C4 of U1 snRNA, whilst U is preferred at +6. As the filter-binding assay described above requires large amounts of U1 snRNP, we studied binding of different 5′SS sequences to U1 snRNP by competition assay using a short, fluorescently-labelled oligonucleotide as a reference ([Table 2](#tbl2){ref-type="table"}). We found that a labelled consensus sequence oligonucleotide bound too tightly to be competed off by the weaker competitor oligonucleotides at concentrations that could be feasibly achieved in the experiment. Hence we used a mismatched labelled oligonucleotide (5SS-F). This does not influence the experiment\'s capacity to show whether one oligonucleotide competes better or worse than another. Single nucleotide substitutions at highly conserved positions substantially reduce the affinity of the 5′SS oligonucleotide for U1 snRNP ([Figure 7C](#fig7){ref-type="fig"}). For example, substitution of G at −1, +1 and +5 with C drastically reduces the binding of the competitor oligonucleotide ([Figure 7C](#fig7){ref-type="fig"}) as C does not form a stable basepair with C ([@bib23]). Furthermore, substitution of +2U with an A severely reduces the binding affinity, presumably because an A--A mismatch distorts and destabilizes the duplex itself ([@bib23]) ([Figure 7C](#fig7){ref-type="fig"}). The affinity of +2C 5′SS RNA is higher than that of +2A ([Figure 7C](#fig7){ref-type="fig"}) presumably because cytosine could form a wobble basepair with a protonated A ([@bib12]; [@bib18]; [@bib65]). This is consistent with the fact that C is found at +2 position, although very infrequently. G at +3 and +4 could form a wobble basepair with Ψ6 and Ψ5, respectively, and substitution of A with G at +3 or +4 position has only a moderate effect on the affinity ([Figure 7D](#fig7){ref-type="fig"}). The 5′SS with a G − Ψ wobble basepair at +4 position (+4G) has higher affinity than the one at +3 position (+3G) ([Figure 7C](#fig7){ref-type="fig"}) whilst +3G occurs more frequently in human genes ([Figure 7B](#fig7){ref-type="fig"}) than +4G. [@bib47] reported the effect of three single base substitutions in the 5′SS on the melting temperature of the duplex between 5′SS oligonucleotides and an oligonucleotide representing the 5′-end of U1 snRNA. +1A and +2C both had severe effects on melting temperature, in agreement with our results. Most other mutations they studied introduced a bulged nucleotide. Here we did not include such 5′SS oligonucleotides in our analysis, as it is hard to predict the effect of the bulged nucleotide on the molecular contacts observed in our crystal structure. We next studied binding of the same set of the 5′SS oligonucleotides to U1 snRNP in the absence of U1-C (U1 snRNP\[ΔU1-C\]) to see how U1-C contributes to the selection of 5′SS oligonucleotides ([Figure 7E,F](#fig7){ref-type="fig"}). To a first approximation these 5′SS mutants show very similar affinities relative to the wild type both in the absence and presence of U1-C, enforcing the notion that 5′SS are selected primarily by U1 snRNA. In the absence of U1-C, the mutant 5′SS oligonucleotides with +3G or +4G compete well with the wild type as in the presence of U1-C but other oligonucleotides with +3U, +4U, +1C, −1C or +5C mutations compete better in the presence of U1-C than in its absence. This shows that U1-C fine-tunes the affinity of these mismatched oligonucleotides, in most sequences studied here, to provide extra stabilisation relative to the wild type. For example, in the presence of U1-C the oligonucleotides with +3U or +4U, which introduce U--U mismatches, compete better with the wild type than they do in the absence of U1-C. Different types of U--U basepair have been reported ([@bib28]; [@bib23]; [@bib21]; [@bib55]). Our crystal structure showed that U1-C forms hydrogen bonds exclusively with sugar-phosphate backbone between −2 to +3 positions of pre-mRNA and at C9 and G11 of U1 snRNA ([Figure 4B--C](#fig4){ref-type="fig"}). When extra hydrogen bonding groups are provided by U1-C, the U--U pair could easily switch from one type to another. It is conceivable that these amino acid residues of U1-C could provide extra stabilization for these non-canonical basepairs, possibly by altering helical geometry and/or minor groove width.10.7554/eLife.04986.015Table 2.5′splice site binding**DOI:** [http://dx.doi.org/10.7554/eLife.04986.015](10.7554/eLife.04986.015)Oligo nameSequence[\*](#tblfn4){ref-type="table-fn"}**5ss-FAGGAAAGUAU-F**[†](#tblfn5){ref-type="table-fn"}WTCAAAGGUAAGUUGGA−1CCAAA**C**GUAAGUUGGA+1CCAAAG**C**UAAGUUGGA+2ACAAAGG**A**AAGUUGGA+2CCAAAGG**C**AAGUUGGA+3UCAAAGGU**U**AGUUGGA+3GCAAAGGU**G**AGUUGGA+4UCAAAGGUA**U**GUUGGA+4GCAAAGGUA**G**GUUGGA+5CCAAAGGUAA**C**UUGGA[^6][^7]

It has been proposed that U1 snRNP selects the same 5′SS sequence even in the absence of the 5′-end of U1 snRNA ([@bib8]; [@bib29]), and that U1C in isolation can recognize the 5′SS sequence. This conclusion is mainly based on a SELEX experiment, which may have been prone to an artefact caused by incomplete removal of the 5′-end of U1 snRNA. We observed no binding of 5′SS oligonucleotide by human U1-C protein, which was shown to be properly folded by NMR ([@bib34]). [@bib53] investigated the role of conserved basic and hydrophilic residues in yeast U1-C: they mutated residues that form hydrogen bonds with the backbone atoms of either 5′SS (Thr11, Thr14, Tyr12 and His24) or U1 snRNA (His15 and Ser19), form a salt-bridge with SmD3 (Arg21) or lie near the phosphate backbone (Lys22 and Arg28 \[Lys28 in yeast\]) in our crystal structure ([Figure 4](#fig4){ref-type="fig"}). Substitution of any one of these residues with Ala had no effect on yeast growth at any temperature indicating that these mutations do not have a major influence on 5′SS selectivity, in agreement with our conclusion.

Conclusions {#s2-3}
-----------

The structures of two sub-domains of U1 snRNP reported here have revealed an intricate network of interactions between the components of U1 snRNP. U1-70k N-terminal peptide binds to the subunit interfaces between SmD2 and SmF, and between SmD3 and SmB, and hence only the fully-formed core domain can induce its binding, which in turn enables U1-C to bind the core domain. Our structure also revealed the molecular contacts between U1 snRNP and the 5′SS of pre-mRNA and provided new insights into the molecular mechanism of 5′SS selection. U1-C makes no contacts with nucleotide bases and U1 snRNP selects 5′SS sequences primarily by thermodynamic stability of the RNA duplex between the 5′-end of U1 snRNA and the 5′SS. However U1-C fine-tunes the affinity to stabilize the binding of some mismatched 5′SS oligonucleotides relative to the canonical 5′SS.

Materials and methods {#s3}
=====================

Protein preparation {#s3-1}
-------------------

The SmE/SmF/SmG trimer, the SmD1/SmD2 dimer, the SmB/SmD3 dimer, U1-A, U1-70k and U1-C were prepared as described previously ([@bib39]; [@bib19]; [@bib34]; [@bib41]; [@bib27]). All proteins are based on human sequences, unless otherwise indicated. The coding sequence of thioredoxin, (His)~6~-tag, tobacco etch virus (TEV) protease cleavage site, and a U1-70K fragment (residues Thr 2--Arg 59) was PCR-amplified from the U1-70K expression vector and inserted at the initiation codon of SmD1 in the SmD1/SmD2 coexpression vector ([@bib19]) to create the U1-70kSmD1/SmD2 expression vector ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). A (Gly--Ser)~3~ sequence was included in the PCR primer to link the U1-70k fragment to SmD1. *Escherichia coli* BL21 (DE3) pLysS cells were transformed with the expression vector ([@bib61]). The cells were grown at 37°C in 2xTY medium with ampicillin (100 μg/ml) and, when A~600\ nm~ = 0.4 − 0.8, protein expression was induced by addition of 0.5 mM IPTG and the culture was continued at 15°C overnight. Cell pellets were resuspended in Ni-A buffer (20 mM Tris-Cl pH7.4, 1 M NaCl, 1 M urea, 10 mM 2-mercaptoethanol) supplemented with EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland). The cells were lysed by sonication and clarified lysate was loaded onto a Ni-NTA column. The protein was eluted with a gradient of imidazole to 300 mM. The thioredoxin and (His)~6~-tags of the protein were cleaved by His-tagged TEV protease during dialysis against Ni-A buffer before passing through the Ni-NTA column again. The flowthrough fractions were diluted fivefold with Na-0 buffer (20 mM Tris-Cl pH7.4, 1 M urea, 10 mM 2-mercaptoethanol) and loaded onto a HiTrap heparin column (GE Healthcare, Little Chalfont, UK) equilibrated with heparin-A buffer (20 mM Tris pH7.4, 200 mM NaCl, 1 M urea, 10 mM 2-mercaptoethanol). The U1-70kSmD1/SmD2 heterodimer was eluted by a NaCl gradient and peak fractions were pooled, concentrated to ∼300 µM, rapidly frozen in liquid nitrogen and stored at −80°C.

A coding sequence for U1A70kF, ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) consisting of a (His)~6~-tag, TEV-protease cleavage site, residues 2--111 of U1-A protein, a linker of six Gly--Ser repeats and residues 60--216 of U1-70k protein, was constructed from PCR fragments and synthetic oligonucleotides, and ligated into the pET13 vector. *E. coli* BL21 (DE3) pLysS cells were transformed with the expression vector ([@bib61]) and cells were grown in 2xTY medium with ampicillin (50 μg/ml) and chloramphenicol (34 μg/ml) at 37°C until A~600\ nm~ was approximately 0.7. Then, the temperature was lowered to 20°C and protein expression induced by addition of 0.5 mM IPTG. After 8--10 hr cells were harvested by centrifugation and resuspended in lysis buffer (20 mM Na^+^-Hepes pH 7.5, 25 mM imidazole, 0.5 M NaCl, 0.5 M urea). The cells were lysed by sonication, clarified and loaded onto a Ni-NTA column. The U1A70kF protein was eluted by a linear gradient of 25--500 mM imidazole in the same buffer. The His-tag was cleaved off with His-tagged TEV protease and the uncleaved protein was removed by passing the protein through a second Ni-NTA column. The protein was loaded onto a heparin-Sepharose column and eluted with a linear NaCl gradient (120--1000 mM) in 20 mM Na^+^-Hepes pH 7.5, 25 mM Imidazole, 60 mM Na Phosphate pH 7.4, 1 M urea. Peak fractions were concentrated by ultrafiltration, buffer exchanged into 20 mM Na.Hepes, 25 mM imidazole, 0.3 M NaCl, pH 7.5, rapidly frozen in liquid nitrogen and stored at −80°C.

RNA preparation {#s3-2}
---------------

DNA templates for in vitro transcription ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) were assembled by ligating overlapping oligonucleotides, which included the T7 promoter, into pUC18 vector. All RNAs are based on human sequences, unless otherwise indicated. Genes for full-length and minimal U1 snRNAs lacking the first 10 nucleotides were also cloned into pUC18 together with T7 promoter. These truncated RNAs were transcribed in the presence of 2 mM GMP to facilitate ligation of modified 5′ end oligonucleotides. The 5′ fragment of U1 snRNA with post-transcriptional modifications (5′-AmUmACΨΨACCU-3′ or 5′-AmUmACUUACCU-3′ where Ψ = pseudo-uridine, Am, Um = 2′-O-methyl nucleotides) were purchased from Dharmacon (GE Healthcare, Little Chalfont, UK) and ligated to the truncated U1 snRNAs by splint-assisted ligation with T4 DNA ligase ([@bib38]). The plasmid template preparation, in vitro transcription and purification of RNA were carried out as described ([@bib42]).

In vitro reconstitution and purification of full-length U1 snRNP {#s3-3}
----------------------------------------------------------------

The full-length U1 snRNA at 8 µM was incubated in 50 mM KCl at 80°C for 2 min and annealed by snap cooling on ice. Three Sm protein sub-complexes were diluted to 100 μM each in reconstitution buffer (RB: 250 mM KCl, 20 mM K^+^-HEPES pH 7.5, 5 mM DTT). RNA was mixed with Sm proteins so that the solution contained 4 μM of RNA, 6 μM of each of the Sm proteins, 10 mM of DTT, and 40 units/ml of RNasin (Promega, Fitchburg, Wisconsin, USA) in RB. The mixture was incubated at 30°C for 30 min, and then at 37°C for 15 min. U1-70k was diluted to 12 μM with RB. The Sm protein-RNA complex was mixed with an equal volume of the U1-70k solution and incubated on ice for 15 min. U1-A protein was added to 4 μM final concentration. The final reconstitution mix contained 2 μM of RNA, 3 μM each of the Sm proteins, 4 μM of U1-A, and 6 μM of U1-70k protein in RB. The solution was incubated on ice overnight and applied to a monoQ column (GE Healthcare, Little Chalfont, UK). The reconstituted complex was eluted with a gradient of KCl from 250 mM to 1 M in RB buffer. U1-C protein was added to U1 snRNP by buffers supplemented with 1.5 μM of U1-C protein to ensure an excess of U1-C in binding assays.

In vitro reconstitution of minimal U1 snRNP {#s3-4}
-------------------------------------------

2 µM of SmKCm RNA ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}) was mixed with 1.5-fold molar excess of U1-70kSmD1/SmD2, SmD3/SmB and SmE/SmF/SmG sub-complexes in RB supplemented with 2 M urea. After incubation at 37°C for 1 hr, the sample was dialyzed against RB buffer at 4°C overnight. U1-C protein was added to a final concentration of 6 µM and incubated at 30°C for 15 min and at 4°C for at least 1 hr. The complex was purified on a monoQ column as described for full-length U1 snRNP.

In vitro reconstitution of U1A70kF complex with SL1·SL2 RNA {#s3-5}
-----------------------------------------------------------

U1A70kF protein was added slowly to 10 μM SL1·SL2 RNA in 0.4 M NaCl, 40 mM Na^+^-Hepes pH 7.5, 50 mM imidazole at room temperature for a final protein concentration of 15 μM. After 20 min the mixture was diluted with an equal volume of water and incubated for a further 10 min. The complex was purified on a monoQ column equilibrated with 20 mM Na^+^-Hepes pH 7.5, 150 mM NaCl and eluted with a NaCl gradient (150 mM--1 M). Peak fractions were pooled, concentrated to 6 mg/ml with a centrifugal concentrator, and buffer exchanged into 0.2 M NaCl, 20 mM Na^+^-Hepes pH 7.5, 25 mM imidazole.

Crystallization of the minimal U1 domain {#s3-6}
----------------------------------------

Crystals of the SmKCm complex were obtained by sitting-drop vapour diffusion at 277K. The purified U1 snRNP complex was mixed with 1.2-fold molar excess of 5′SS RNA oligo (5′-AGGUAAGUCC-3′) purchased from Dharmacon (GE Healthcare, Little Chalfont, UK) and 0.15 mM of polyamine-9 ([@bib50]). The complex solution (4 mg/ml in 300 mM KCl, 20 mM K^+^-Hepes, pH 7.5, 5 mM MgCl~2~, 1 mM DTT) was mixed with an equal volume of reservoir solution (7% MPD, 180 mM KCl, 5 mM MgSO~4~, 50 mM Na^+^-Hepes pH 6.4). The crystals were improved by streak-seeding from another crystallization drop using a feline whisker 3 min after mixing the drops. Crystals suitable for data collection appeared after 1 month, reaching maximum dimensions of 0.35 × 0.05 × 0.05 mm^3^. Crystals were transferred to cryo-protection buffer (20% MPD, 200 mM KCl, 5 mM MgSO~4~, 50 mM Na^+^-Hepes pH 6.4, 25% PEG4000) in three steps with 30 min equilibration after each transfer and flash frozen in liquid nitrogen.

Crystallization of the U1A70kF RNA complex {#s3-7}
------------------------------------------

The U1A70kF RNA complex was mixed with an equal volume of 40% MPD, 0.15 M NaCl, 0.1 M sodium acetate pH 4.2 and equilibrated with the same solution by sitting drop vapour diffusion at 20°C. Crystals of type I (wedge-shaped) grew within 16--48 hr whereas crystals of type II (plate-like) grew in the same drops after several weeks. Only the latter type diffracted to sufficient resolution for a structure determination.

Structure determination {#s3-8}
-----------------------

Diffraction data were collected at Diamond Light Source beamlines I02, I03, I04 and I04-1. Data were integrated in iMosflm ([@bib25]) and scaled with Scala ([@bib5]). For the minimal U1 snRNP (SmKCm complex) an initial molecular replacement solution was found in Phaser ([@bib32]) using the U4 snRNP core domain proteins ([@bib27]). These form similar ring structures in both U1 and U4 snRNP, and have a total mass of ∼70 kDa, which is more than half the mass of the minimal U1 snRNP (∼120 kDa). Phases were improved by density modification using Parrot ([@bib6]). This allowed us to build the remainder of the model using Coot ([@bib9]). The N-terminal region of U1-70k was built de novo and we manually placed the zinc finger domain of U1-C protein ([@bib34]) and HIV1 kissing loop structure ([@bib10]) into electron density. The structure was refined by Refmac ([@bib33]) ([Table 1](#tbl1){ref-type="table"}). For the U1A70kF-RNA complex, an initial molecular replacement solution was found in Phaser ([@bib32]) using part of the structure of U1-A complex with SL2 RNA ([@bib39]) and a homology model of the U1-70k RRM, which was built with Modeller ([@bib30]) using multiple templates and manually refined alignment as an input. The remainder of the model was built into the MR map using Coot ([@bib9]), and the structure was refined by Refmac ([@bib33]) ([Table 1](#tbl1){ref-type="table"}). Figures of molecular structures were drawn using Pymol ([www.pymol.org](http://www.pymol.org)).

Pre-mRNA binding assays {#s3-9}
-----------------------

Pre-mRNA oligonucleotide substrates containing 5′ splice-site sequences were purchased from Dharmacon (GE Healthcare, Little Chalfont, UK) ([Table 2](#tbl2){ref-type="table"}). All the components were diluted in binding assay buffer (BAB: 10 mM K^+^-Hepes pH7.5, 200 mM KCl, 2 mM MgCl~2~, 0.5 mM DTT, 100 µg/ml tRNA, 50 µg/ml BSA), and 1.5 µM U1-C protein was added to BAB to ensure saturation of U1 snRNP with U1-C protein under assay conditions. In competition assays, each reaction (16 μl) containing 1 nM fluorescein-labeled reference RNA oligo (5ss-F) and 35 nM U1 snRNP reconstituted with U1 + Ψ RNA ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), was titrated with non-labelled competitor 5′SS RNA oligos. Binding curves were measured by fluorescence polarization using Pherastar (BMG Labtech, Ortenberg, Germany). The assays were carried out in triplicate. The values of fluorescence polarization in the absence of competitor RNA oligo were plotted at 1 pM for reference.

In the filter-binding assay, a 5′SS RNA oligonucleotide (5′-^32^P- CAAAGGUAAGAUGGA-3′, 10 fmol), was mixed with various concentrations of U1 snRNP, with or without U1-C protein, in Filter-Binding Buffer (FBB: 200 mM KCl, 2 mM MgCl~2~, 0.5 mM DTT, 10 mM Hepes, pH 7.5, 100 µg/ml tRNA, 50 µg/ml BSA) in a final volume of 40 µl and incubated at 22°C for 2 hr. The binding reaction was passed, under vacuum, through a Schleicher & Schuell (Dassel, Germany) NC45, 25 mm diameter filter that had been pre-wetted with FBB. The filter was washed with 0.5 ml FBB and then dried. The proportion of radiolabeled oligonucleotide retained on the filter was determined by scintillation counting. The experiment was performed in triplicate.
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KondoY, OubridgeC, van RoonAM, NagaiK, 2014,Minimal U1 snRNP,<http://www.pdb.org/pdb/search/structidSearch.do?structureId=4pjo>,Publicly available at NCBI Protein Data Bank.
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**Reporting Standards:** Standard used to collect data: Validation reports are included in the data base.

The following previously published dataset was used:

LeungAKW, NagaiK, LiJ, 2014,Spliceosomal U4 snRNP core domain,<http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WZJ>,Publicly available at NCBI Protein Data Bank.
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As you will see, two of the referees thought that the work was very nice and could be published as is. The third referee agrees that the work is very important and is worthy of publication in *eLife*. However they raise a number of points that must be dealt with via revision. Please address each of these points as thoroughly as possible. When revision is complete resubmit electronically together with a letter detailing all changes.

Reviewer \#1:

This manuscript reports high resolution x-ray structures of two sub-domains of U1 snRNP. The two structures reveal unprecedented insight into the organization of the RNP as well as the mechanism by which this RNP recognizes 5\' splice sites. Both structures contain a wealth of information regarding protein-protein interactions as well as protein-RNA interactions present in the RNP. Perhaps the most surprising aspect of the paper is that the U1-C protein does not make base specific contacts with the 5\' splice site. This finding dispels the currently accepted notion that U1-C participates in 5\' splice site recognition. Overall, the manuscript is exceptionally clearly presented and the results are highly significant. Publication in *eLife* is recommended as is.

*Reviewer \#2*:

The manuscript by Kondo et al. elucidates the mechanism of 5\' splice site recognition. Based on their previous work, the authors cleverly engineered two subcomplexes of the human U1 snRNP and determined their corresponding structures at high resolution. The fundamental importance of this work is that the results explain how the 5\' splice site of a pre-mRNA is recognized by the U1 snRNP. The work is thorough, the data are of high quality, the figures and text are clear, and the message is very important. This is a beautiful piece of work.

Reviewer \#3:

Kondo et al used X-ray crystallography to solve two structures related to the human U1 snRNP. Their structural data conclusively show that the 5′ splice site is recognized via base pairing with U1 snRNA and not another protein in the snRNP complex. Furthermore, the structures establish a network of interactions within the U1 snRNP, particularly U1 snRNA, U1-C, U1-70k and the seven Sm proteins. The authors also employ binding assays to validate the importance of base pairing between U1 snRNA and RNA containing the 5′ splice site.

Overall, the work rests on a long-time controversy in the splicing field; whether the sequence of the 5\'-splice site is recognized by both an RNA and a protein and is therefore worthy of publication in *eLife*. However, several scientific issues need to be addressed and the clarity of the presentation requires significant improvement.

Scientific comments:

1\) Pre-mRNA binding assays: For oligo 5ss-F, the sequence does not appear to be a consensus 5\'-splice site. Thus, the competing oligos have a consensus splice site but the sequence differs by more than a single-nucleotide position. The authors need to explain why these sequences were used or repeat the assay using oligos with the proper sequence.

2\) The main text provides no details about how the crystal structures were determined, i.e. by molecular replacement. The rationale for using the U4 snRNP core domain as a model was not explained. Is it simply because the Sm proteins are shared?

General comments:

Interactions are described extensively throughout this manuscript. However, specific interactions (i.e. amino acid residues and nucleotides) are usually not stated. If specific interactions are mentioned, they often are not labeled in the figures, making it difficult to understand the authors\' interpretation of the structure. More details need to be added to the figure legends to accurately and precisely describe the interactions shown in the figures.

Minor comments:

Abstract:

The resolution of the crystal structures (3.3 and 2.5 Ang) needs to be added. Also, "subdomains" is misleading because this term is not generally applied to the U1 snRNP. Perhaps the authors should use "synthetic substructures" instead.

Introduction:

The range of nucleotides in the invariant sequence is not mentioned. The authors should insert "(nts \#-\#)" to specify the nucleotides of interest?

The Introduction compares 5′SS recognition in yeast and humans. It appears the authors are trying to make the point that this work is focused on the conserved regions. To make this point more clear, perhaps the authors should begin by explaining how the yeast and human U1 snRNPs differ. Although "human" is used in the Title, the authors should reconfirm that all the components in this work are based on human nt sequences and proteins, correct?

The Introduction does not end with a short summary of the major findings of this work, leaving the reader unsatisfied. The last paragraph of the Introduction is a run-on paragraph. The authors should divide the paragraph into two independent paragraphs: one for the yeast-human comparison and one for the reported findings.

The Introduction talks about the role of U1 in splicing. However, there is no mention of its other important cellular function, telescripting.

Results:

The text mentions seven Sm proteins but [Figure 1A](#fig1){ref-type="fig"} labels only five Sm proteins.

"The overall structure of the core domain is very similar to that of the U4 snRNP core domain." Please include rmsd to support the descriptor "very similar". Also, how do you know the similarity is not due to model bias?

Helix H0 and helix H are two examples of features being mentioned that are not shown/labeled.

What are the "key residues"? The residues are also not identified in the figure legend. The reader must guess what residue is at the "equivalent position". Where are loops L3 and L5?

The authors talk about nucleotides yet the exception they list, SmD1, is a protein. This is confusing.

Binding is stabilized by salt bridges and hydrogen bonds -- what residues and/or nucleotides participate?

Because U4 is referred to several times throughout this manuscript, a picture of U4 should be shown in the supplement, explaining what components constitute the "core".

The text specifically identifies strands and helices of importance but these secondary structures are not labeled in the figures (e.g. beta 4 strand in [Figure 3D and 4A](#fig3 fig4){ref-type="fig"}). There are other such omissions throughout the manuscript.

Be quantitative about how much the R21Q mutation weakens binding.

Are pseudo-uridines present in both human and yeast snRNAs?

The "E complex" needs to be defined and its relevance explained for the general reader.

"Conserved well" *--* what exactly is the percentage of sequence similarity?

What is meant by the 11-nt loop effectively being a 5-nt loop? How does base stacking reduce loop length?

C33 and G34 are not labeled in [Fig 5A](#fig5){ref-type="fig"}. In [Fig 5c](#fig5){ref-type="fig"}, the side chains of R191 and K138 should be shown?

The filter binding assay is not adequately described in Materials and methods.

Materials and methods:

1\) Are all proteins and nt sequences based on human?

2\) Prior to the induction step, were cells grown at 15^°^C?

3\) What is the final storage buffer? Was glycerol not added?

4\) No storage conditions are described. Was the protein never frozen?

5\) Steps are described for annealing full-length U1 snRNA but it is not stated to what it is being annealed. Do the authors mean folding rather than annealing? Also, is the annealing step performed in the absence of buffer?

Figures & legends:

The descriptions in the figure legends are inadequate. Many of the figures suffer from the same problems. Please explain what is represented by colored objects and dashed lines in each figure legend. The colors in [Figure 1--figure supplement 1](#fig1s1){ref-type="fig"} are not consistent with [Figure 1](#fig1){ref-type="fig"} (e.g. SmF is brown in [Figure 1](#fig1){ref-type="fig"} but green in the supplement). Please add more information about interactions between specific residues and nucleotides. Make sure key secondary structures, nucleotides and amino acids mentioned in the text are labeled in the figures, especially [Figures 3 and 4](#fig3 fig4){ref-type="fig"}.

[Figure 1](#fig1){ref-type="fig"}: For readers unfamiliar with the U1 snRNP, it would be helpful if there were a cartoon schematic for each crystal structure. Then, it would be easier to visualize the location of each component. Also, [Figure 1](#fig1){ref-type="fig"} could show representative examples of the electron density for each structure. Then, [Figure 2](#fig2){ref-type="fig"} could be deleted and replaced with [Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}, which contains more substantial structural information.

[Figure 1--figure supplement 1](#fig1s1){ref-type="fig"}: What are the black, blue and red lines?

[Figure 2](#fig2){ref-type="fig"}: Is this a stereoview?

[Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}: The legend mentions electron density for A125 in panel A but no density is shown. Please add more details about panels B-H; the amino acid residues are important as well as the nucleotides.

[Figure 4](#fig4){ref-type="fig"}: What do the teal/pale pink colors represent?

[Figure 7](#fig7){ref-type="fig"}: A description of the plots is missing. What are "CPM" and "mP"? Do the error bars represent SD or SE? What are the Kd values extrapolated from the data in [Figure 7A](#fig7){ref-type="fig"}? The text mentions a 4-fold difference but doesn\'t state a numerical value with units. In panels C and E, WT data are missing.

Tables:

In [Table 2](#tbl2){ref-type="table"}, is the sequence for -1C correct? It seems that the red U should be a C.

10.7554/eLife.04986.017

Author response

*Scientific comments*:

*1) Pre-mRNA binding assays: For oligo 5ss-F, the sequence does not appear to be a consensus 5\'-splice site. Thus, the competing oligos have a consensus splice site but the sequence differs by more than a single-nucleotide position. The authors need to explain why these sequences were used or repeat the assay using oligos with the proper sequence*.

We found that a labelled consensus sequence oligonucleotide bound too tightly to be competed off by the weaker competitor oligonucleotides at concentrations that could be feasibly achieved in the experiment. Hence we used a labelled oligonucleotide with one mismatch (5SS-F). This does not influence the experiment\'s capacity to show whether one oligonucleotide competes better or worse than another.

*2) The main text provides no details about how the crystal structures were determined, i.e. by molecular replacement*.

We now make it clear in the main text that both structures were determined by molecular replacement with a sentence added to the end of the first paragraph of the Results section.

The rationale for using the U4 snRNP core domain as a model was not explained. Is it simply because the Sm proteins are shared?

It is now explained in Materials and methods section.

General comments:

*Interactions are described extensively throughout this manuscript. However, specific interactions (i.e. amino acid residues and nucleotides) are usually not stated. If specific interactions are mentioned, they often are not labeled in the figures, making it difficult to understand the authors\' interpretation of the structure. More details need to be added to the figure legends to accurately and precisely describe the interactions shown in the figures*.

We have now labelled amino acid residues and nucleotide as requested in the figures. Chains are coloured consistently throughout the manuscript.

Abstract:

*The resolution of the crystal structures (3.3 and 2.5 Ang) needs to be added. Also, "subdomains" is misleading because this term is not generally applied to the U1 snRNP. Perhaps the authors should use "synthetic substructures" instead*.

The second sentence of the Abstract has been changed to "We present two crystal structures, at 2.5 Å and 3.3 Å resolution, of engineered U1 sub-structures which together reveal\..." Although the term \'synthetic\' was suggested to describe the sub-structures, we believe the term "engineered" already suffice to describe "something which was man-made". Also, we now use the hyphenated term \'sub-structure\', rather than \'substructure\' throughout the text, because the latter only has the dictionary definition, \'an underlying or supporting structure\', which is not the intended meaning.

Introduction:

The range of nucleotides in the invariant sequence is not mentioned. The authors should insert "(nts \#-\#)" to specify the nucleotides of interest?

We inserted (nts1-10).

*The Introduction compares 5′SS recognition in yeast and humans. It appears the authors are trying to make the point that this work is focused on the conserved regions. To make this point more clear, perhaps the authors should begin by explaining how the yeast and human U1 snRNPs differ. Although "human" is used in the Title, the authors should reconfirm that all the components in this work are based on human nt sequences and proteins*, *correct?*

p5: To address several points made about the Introduction, an extra sentence has been added to the 4th paragraph, comparing yeast and human U1 snRNP, and the nucleotide range has been inserted in the subsequent sentence.

"Yeast U1 snRNP, when compared to the human particle, contains a larger and more complex snRNA, which is associated with many protein factors (Prp39, Snu71, Prp40, Prp42, Nam8, Snu56, Urn1 and Prp5), which have no counterparts in human U1 snRNP ([@bib66]). However, despite these differences, the sequence of the 5\'-single stranded region of U1 snRNA (nts 1-10) is invariant from yeast to human".

*The Introduction does not end with a short summary of the major findings of this work, leaving the reader unsatisfied. The last paragraph of the Introduction is a run-on paragraph. The authors should divide the paragraph into two independent paragraphs: one for the yeast-human comparison and one for the reported findings*.

A short summary paragraph has been added to the end of the Introduction.

"The two crystals together reveal the structures of the substantial parts of U1 snRNP at high resolution and provide crucial insights into the mechanism of pre-mRNA recognition by U1 snRNP. In particular, we find that U1-C makes no base-specific contacts with the 5\'SS sequence. Also, by measuring the intrinsic affinity of recombinant U1 snRNP for various 5'SS sequences we disentangle the role played by the U1 snRNP from the other complexities of 5'SS recognition, and assess the relative contributions of U1 snRNA and U1-C protein in light of our crystal structure."

*The Introduction talks about the role of U1 in splicing. However, there is no mention of its other important cellular function, telescripting*.

An extra sentence has been added to the end of paragraph 1, mentioning the role of U1 snRNP in regulating cleavage and polyadenylation of mRNA (telescripting) with two references.

"U1 snRNP is also an important regulator of mRNA 3\' end cleavage and polyadenylation ([@bib1]; reviewed in [@bib59])."

Results:

*The text mentions seven Sm proteins but* [*Figure 1A*](#fig1){ref-type="fig"} *labels only five Sm proteins*.

We have now labelled all components in [Figure 1A](#fig1){ref-type="fig"}.

"The overall structure of the core domain is very similar to that of the U4 snRNP core domain." Please include rmsd to support the descriptor "very similar". Also, how do you know the similarity is not due to model bias?

We included rmsd in the text. The U4 snRNP structure has now been refined to Rfree of 22.4% and the U1 snRNP structure has been refined to Rfree of

25.5%. Hence model bias would not be an issue for ordered regions we discuss in this manuscript. We included rmsd of the two structures in the text.

*Helix H0 and helix H are two examples of features being mentioned that are not shown/labeled*.

It is shown in [Figure 1A](#fig1){ref-type="fig"} and we now refer to this figure in the text.

*What are the "key residues"? The residues are also not identified in the figure legend. The reader must guess what residue is at the "equivalent position"*. *Where are loops L3 and L5?*

The key residues in loops L3 and L5 are now identified in [Figure 2--figure supplement 1](#fig2s1){ref-type="fig"} legend.

*The authors talk about nucleotides yet the exception they list, SmD1, is a protein. This is confusing*.

This has been changed to clarify that nucleotide G130 interacts differently with protein SmD1.

*Binding is stabilized by salt bridges and hydrogen bonds* -- *what residues and/or nucleotides participate?*

We added "its binding to SmD2 is stabilized..." to clarify this statement.

*Because U4 is referred to several times throughout this manuscript, a picture of U4 should be shown in the supplement, explaining what components constitute the "core"*.

We added "which consists of seven Sm proteins and U4 snRNA when the U4 core snRNP first appears".

*The text specifically identifies strands and helices of importance but these secondary structures are not labeled in the figures (e.g. beta 4 strand in* [*Figure 3D and 4A*](#fig3 fig4){ref-type="fig"}*). There are other such omissions throughout the manuscript*.

See [Figure 3D](#fig3){ref-type="fig"}. We do not consider it necessary to label the 3~10~ helix of U1-70k in [Figure 4A](#fig4){ref-type="fig"} because this helix is defined as residues 6-12 in the text and the start and end residues (Pro6 and Leu12) are labeled in the figure. Furthermore, this region of the figure is already quite crowded.

*Be quantitative about how much the R21Q mutation weakens binding*.

We added "by about 10-fold" to this sentence.

*Are pseudo-uridines present in both human and yeast snRNAs*?

Pseudo-uridines are conserved at the 5\' end of U1 snRNA of yeast and human. The following has been added to paragraph 4 of the Results section and a supporting reference has been added to References (see below).

"Pseudo-uridines at these positions are conserved from yeast to human U1 snRNA ([@bib31])."

*The "E complex" needs to be defined and its relevance explained for the general reader*.

"At an early stage of spliceosomal assembly U1 snRNP binds to the 5'SS and U2 auxiliary factor (U2AF) and splicing factor 1 (SF1) bind to the 3' splice site and branch point resulting in the formation of E complex." This has been inserted before the sentence to define the E complex.

"Conserved well" -- what exactly is the percentage of sequence similarity?

"The first 215 residues of U1-70k are conserved well from yeast to human (48% sequence similarity), suggesting that this region has an evolutionarily conserved essential function".

What is meant by the 11-nt loop effectively being a 5-nt loop? How does base stacking reduce loop length?

This is illustrated in [Figure 5 A and C](#fig5){ref-type="fig"}.

*C33 and G34 are not labeled in* [*Fig 5A*](#fig5){ref-type="fig"}. *In* [*Fig 5c*](#fig5){ref-type="fig"}*, the side chains of R191 and K138 should be shown?*

Labels for C33 and G34 and the side chains of R191 and K138 have been added to [Figure 5A](#fig5){ref-type="fig"}.

*The filter binding assay is not adequately described in Materials and methods*.

See Materials and methods, end of final section.

\'Mechanism of 5\'SS recognition\', first paragraph: to be more accurate about U1 snRNP affinity for 5\'SS RNA ±U1-C, the penultimate sentence has been altered.

"The affinity of U1 snRNP without U1-C (U1 snRNP( U1-C)) for the wild type 5'SS oligonucleotide increases by between three and four-fold on addition of U1-C ([Figure 7A](#fig7){ref-type="fig"})."

Materials and methods:

1\) Are all proteins and nt sequences based on human?

"All proteins are based on human sequences, unless otherwise indicated" was added as the second sentence in the Protein Preparation section and the sentence. "All RNAs are based on human sequences, unless otherwise indicated" was added to the RNA Preparation section.

*2) Prior to the induction step, were cells grown at 15*^*°*^*C?*

The growth temperature prior to induction has been added.

"The cells were grown at 37°C in 2xTY medium with ampicillin (100 ∝g/ml) and, when A~600\ nm~ = 0.4-0.8, protein expression was induced by addition of 0.5 mM IPTG and the culture was continued at 15°C overnight."

3\) What is the final storage buffer? Was glycerol not added?

The given method is correct; no glycerol was added. However, the complex was flash-frozen in liquid nitrogen before storage and an explanatory clause has been added.

"The U1-70kSmD1/SmD2 heterodimer was eluted by a NaCl gradient and peak fractions µM, were pooled, concentrated to ∼300 rapidly frozen in liquid nitrogen and stored at -80°C."

4\) No storage conditions are described. Was the protein never frozen?

Storage conditions have been added as follows:

"Peak fractions were concentrated by ultrafiltration, buffer exchanged into 20 mM Na.Hepes, 25 mM imidazole, 0.3 M NaCl, pH 7.5, rapidly frozen in liquid nitrogen and stored at -80°C."

5\) Steps are described for annealing full-length U1 snRNA but it is not stated to what it is being annealed. Do the authors mean folding rather than annealing? Also, is the annealing step performed in the absence of buffer?

The term annealing is commonly used to refer to the process of folding RNA by heating and subsequent cooling. We do not believe there is any ambiguity here. It is correct that the annealing was performed in the absence of buffer; optimal conditions were found empirically to be in 50 mM KCl.

End of final section: Added description of Filter-Binding Assay.

"In the filter-binding assay, a 5\'SS RNA oligonucleotide (5\'-^32^P-CAAAGGUAAGAUGGA-3\', 10 fmol), was mixed with various concentrations of U1 snRNP, with or without U1-C protein, in Filter Binding Buffer (FBB: 200mM KCl, 2 mM MgCl~2~, 0.5 mM DTT,µg/mL10tRNA,mM Hepes, pH 7.5, 100 50µg/mL BSA) in a final volume of 40 µl and incubated at 22°C for 2 hours.

The binding reaction was passed, under vacuum, through a Schleicher & Schuell NC45, 25 mm diameter filter that had been pre-wetted with FBB. The filter was washed with 0.5 mL FBB and then dried. The proportion of radiolabeled oligonucleotide retained on the filter was determined by scintillation counting. The experiment was performed in triplicate."

Figures & legends:

*The descriptions in the figure legends are inadequate. Many of the figures suffer from the same problems. Please explain what is represented by colored objects and dashed lines in each figure legend. The colors in* [*Figure 1--figure supplement 1*](#fig1s1){ref-type="fig"} *are not consistent with* [*Figure 1*](#fig1){ref-type="fig"} *(e.g. SmF is brown in* [*Figure 1*](#fig1){ref-type="fig"} *but green in the supplement). Please add more information about interactions between specific residues and nucleotides. Make sure key secondary structures, nucleotides and amino acids mentioned in the text are labeled in the figures, especially* [*Figures 3 and 4*](#fig3 fig4){ref-type="fig"}.

[*Figure 1*](#fig1){ref-type="fig"}*: For readers unfamiliar with the U1 snRNP, it would be helpful if there were a cartoon schematic for each crystal structure. Then, it would be easier to visualize the location of each component. Also,* [*Figure 1*](#fig1){ref-type="fig"} *could show representative examples of the electron density for each structure. Then,* [*Figure 2*](#fig2){ref-type="fig"} *could be deleted and replaced with* [*Figure 2--figure supplement 1*](#fig2s1){ref-type="fig"}*, which contains more substantial structural information*.

[Figure 1A](#fig1){ref-type="fig"}: Labels for SmB and SmD1 were not put on this figure because these proteins are mostly concealed at the back of the Sm ring. Labels have now been added to indicate their position and color-coding. The positions of RNA Helix H and SmD2 helix H0 are now also indicated on the figure.

[Figure 1](#fig1){ref-type="fig"} legend: This sentence has been added to part A to explain the labels H and H0 in panel A.

"Label H indicates U1 snRNA helix H; H~0~ indicates the first alpha helix of SmD2 protein."

[*Figure 1--figure supplement 1*](#fig1s1){ref-type="fig"}*: What are the black, blue and red lines?*

In response to the general comment, this figure has been re-colored to be properly consistent with [Figure 1](#fig1){ref-type="fig"}.

[Figure 1--figure supplement 1](#fig1s1){ref-type="fig"} legend:

"The thinner lines below the bars represent the constructs used for crystallization: blue lines for sequences used in the U1A70kF fusion protein, red lines for sequences used in the 70kSmD1F fusion protein, and black lines indicate the extent of protein constructs used in minimal U1 crystallisation."

[*Figure 2*](#fig2){ref-type="fig"}*: Is this a stereoview?*

First line now indicates that this is a stereoview.

"Stereoview showing binding of U1 snRNA at the central hole of the Sm protein assembly."

[*Figure 2--figure supplement 1*](#fig2s1){ref-type="fig"}*: The legend mentions electron density for A125 in panel A but no density is shown. Please add more details about panels B-H; the amino acid residues are important as well as the nucleotides*.

This sentence has been moved into the [Figure 2](#fig2){ref-type="fig"} legend from the legend for [Figure 2--figure supplement 1](#fig2s1){ref-type="fig"} and altered slightly for clarity.

"Electron density for A125 and the phenol ring of SmF Y39, which stacks on it, is weak."

[Figure 2--figure supplement 1](#fig2s1){ref-type="fig"} legend: Has been re-written to address the comments about loops L3 and L5 and \'key residues\' made regarding Results section.

[*Figure 4*](#fig4){ref-type="fig"}*: What do the teal/pale pink colors represent?*

The meaning of the teal and pale pink (fawn) nucleotides is explained.

"(B) U1-C forms hydrogen bonds with the sugar-phosphate backbone atoms but makes no contact with RNA bases. On the 5\'SS strand, nucleotides are colored teal for exonic and fawn for intronic sequence. (C) Schematic representation of the 5\'-splice site recognition. Red dotted lines, hydrogen bonds made by amino acid side chains of U1-C; blue dotted lines, hydrogen bonds made by main chain atoms of U1-C. The 5\'SS nucleotides are color-coded as in panel B."

[*Figure 7*](#fig7){ref-type="fig"}*: A description of the plots is missing. What are "CPM" and "mP"? Do the error bars represent SD or SE? What are the Kd values extrapolated from the data in* [*Figure 7A*](#fig7){ref-type="fig"}*? The text mentions a 4-fold difference but doesn\'t state a numerical value with units. In panels C and E, WT data are missing*.

[Figure 7A](#fig7){ref-type="fig"} legend: Made clear that the graph is of the results of a filter-binding experiment, added Kd values from filter-binding and defined \'CPM\'.

"(A) Filter-binding results for U1 snRNP reconstituted with and without U1-C to \[^32^P\]-labelled 5'splice site oligonucleotide. By curve fitting, the Kd with U1-C is 4.7 ± 0.8 nM and without U1-C is 15.8 ± 2.5 nM. CPM, counts per minute."

[Figure 7C](#fig7){ref-type="fig"} legend: A sentence has been added to the end of this section of the legend defining \'mP\' and explaining the error bars.

"In panels C-F, mP is an arbitrary unit of fluorescence polarization and error bars indicate standard error."

Instead of WT, we use the +2C data to compare [Figures 7C to 7D](#fig7){ref-type="fig"} and [Figures 7E to 7F](#fig7){ref-type="fig"}; this prevents the figures from looking too crowded.

Tables:

*In* [*Table 2*](#tbl2){ref-type="table"}*, is the sequence for -1C correct? It seems that the red U should be a C*.

The sequence for -1C was indeed incorrect. This row has been amended. We have also removed rows -2U and +6A because these sequences weren\'t used in the experiments reported in this paper. A wild-type (WT) row has been added for the reader\'s reference.

[^1]: These authors contributed equally to this work.

[^2]: California Institute for Quantitative Biosciences, University of California, Berkeley, Berkeley, United States.

[^3]: Merging R factor.$$R_{merge} = {\sum\limits_{hkl}{\sum\limits_{i}\left| {I_{i}\left( hkl \right) - \overline{I\left( hkl \right)}} \right|}}/{\sum\limits_{hkl}{\sum\limits_{i}{I_{i}\left( hkl \right)}}}$$.

[^4]: Precision-indicating merging R factor.$$R_{p.i.m} = {\sum\limits_{hkl}{\left\lbrack {1/\left( N - 1 \right)} \right\rbrack^{1/2}{\sum\limits_{i}\left| {I_{i}\left( hkl \right) - \overline{I\left( hkl \right)}} \right|}}}/{\sum\limits_{hkl}{\sum\limits_{i}{I_{i}\left( hkl \right)}}}$$.

[^5]: Calculated in Coot ([@bib9]).

[^6]: **Bold** nucleotides highlight the position of mismatch.

[^7]: F denotes 3′-fluorescein label.
